

George A Karpouzas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7691105/publications.pdf>

Version: 2024-02-01

33
papers

817
citations

687363

13
h-index

526287

27
g-index

33
all docs

33
docs citations

33
times ranked

1202
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum cholesterol loading capacity of macrophages is regulated by seropositivity and C-reactive protein in rheumatoid arthritis patients. <i>Rheumatology</i> , 2023, 62, 1254-1263.	1.9	3
2	The impact of statins on coronary atherosclerosis progression and long-term cardiovascular disease risk in rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 1857-1866.	1.9	8
3	Lipoprotein oxidation may underlie the paradoxical association of low cholesterol with coronary atherosclerotic risk in rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2022, 129, 102815.	6.5	6
4	Beta-2-glycoprotein-I IgA antibodies predict coronary plaque progression in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 20-27.	3.4	7
5	Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). <i>RMD Open</i> , 2021, 7, e001465.	3.8	9
6	Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of evidence and mechanistic insights. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 355-374.	3.0	9
7	Epicardial Adipose Tissue Volume As a Marker of Subclinical Coronary Atherosclerosis in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1412-1420.	5.6	6
8	Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. <i>RMD Open</i> , 2021, 7, e001724.	3.8	12
9	Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , 2021, 40, 5055-5065.	2.2	2
10	Impact of Cumulative Inflammation, Cardiac Risk Factors, and Medication Exposure on Coronary Atherosclerosis Progression in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2020, 72, 400-408.	5.6	49
11	Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 104-114.	3.0	25
12	Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients. <i>Rheumatology</i> , 2020, 59, 1997-2004.	1.9	29
13	Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models. <i>Arthritis Research and Therapy</i> , 2020, 22, 90.	3.5	11
14	Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High-Risk Lesions. <i>Arthritis and Rheumatology</i> , 2020, 72, 1467-1475.	5.6	53
15	AB1150â€¦IMPLICATIONS OF CORONARY ARTERY CALCIUM AND ITS PROGRESSION AS MARKERS OF PLAQUE VULNERABILITY AND PATIENT RISK IN RHEUMATOID ARTHRITIS. , 2019, , .		0
16	SAT0109â€¦SMOKING CESSATION IN PATIENTS WITH RA IS ASSOCIATED WITH REDUCED CVD EVENT RATES AND IMPROVED LIPID PROFILES AND PREDICTS LOWER RA DISEASE ACTIVITY. , 2019, , .		0
17	SAT0095â€¦MEDICATION NECESSITY AND CONCERN BELIEFS ARE DISTINCT, INTERACTIVE PREDICTORS OF TREATMENT ADHERENCE IN RHEUMATOID ARTHRITIS. , 2019, , .		0
18	THU0611â€¦SERUM HIGHLY-SENSITIVE CARDIAC TROPONIN-I AND ANTI-BETA2-GLYCOPROTEIN-1 IGA ANTIBODIES AT BASELINE PREDICT CORONARY PLAQUE PROGRESSION IN RHEUMATOID ARTHRITIS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
19	FRI0051â€¦DURATION OF EXPOSURE TO BIOLOGICS AND STATINS MODERATES THE EFFECTS OF CUMULATIVE INFLAMMATION ON CORONARY ATHEROSCLEROSIS PROGRESSION IN RHEUMATOID ARTHRITIS. , 2019, , .		0
20	THU0083â€¦ROLE OF CLINICAL IMPACT, DISEASE-SPECIFIC KNOWLEDGE AND BELIEFS ABOUT MEDICATION ON THERAPEUTIC ADHERENCE IN RHEUMATOID ARTHRITIS: AN INTEGRATIVE STRUCTURAL EQUATION MODELING APPROACH. , 2019, , .		0
21	High-sensitivity cardiac troponin I is a biomarker for occult coronary plaque burden and cardiovascular events in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 1080-1088.	1.9	24
22	Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 48-54.	0.9	194
23	Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study. <i>RMD Open</i> , 2018, 4, e000731.	3.8	10
24	Latent profile analysis approach to the relationship between patient and physician global assessments of rheumatoid arthritis activity. <i>RMD Open</i> , 2018, 4, e000695.	3.8	6
25	Trends in Functional Disability and Determinants of Clinically Meaningful Change Over Time in Hispanic Patients With Rheumatoid Arthritis in the US. <i>Arthritis Care and Research</i> , 2017, 69, 294-298.	3.4	15
26	Identification and Treatment Optimization of Comorbid Depression in Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2017, 4, 281-291.	2.3	11
27	Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2001-2008.	0.9	55
28	Discordant patientâ€™physician assessments of disease activity and its persistence adversely impact quality of life and work productivity in US Hispanics with rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000551.	3.8	17
29	Towards the identification of multi-parametric quantitative MRI biomarkers in lupus nephritis. <i>Magnetic Resonance Imaging</i> , 2015, 33, 1066-1074.	1.8	34
30	Troxis necrosis, a novel mechanism for drug-induced hepatitis secondary to immunomodulatory therapy. <i>Experimental and Molecular Pathology</i> , 2015, 99, 341-343.	2.1	7
31	Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1797-1804.	0.9	149
32	Correlates and predictors of disability in vulnerable US Hispanics with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1274-1281.	3.4	35
33	Differences between CD8+ Tâ€™cells in lupus-prone (NZBÃ— NZW) F1 mice and healthy (BALB/cÃ— NZW) F1 mice may influence autoimmunity in the lupus model. <i>European Journal of Immunology</i> , 2004, 34, 2489-2499.	2.9	31